• Implantica will hold a capital markets day in Stockholm on Sept. 9, 2026, scheduled for 14:00–16:30 CEST.
• Agenda centers on plans following FDA clearance for RefluxStop, including the US launch strategy.
• Management presentations will be joined by RefluxStop surgeons, with patient perspectives included.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Implantica AG published the original content used to generate this news brief via Cision (Ref. ID: 202609080200BITN____UKPR__SV_20260908-BIT-7446-0) on September 08, 2026, and is solely responsible for the information contained therein.